Last updated: July 12, 2022
Sponsor: Heidelberg University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Pulmonary Arterial Hypertension
Williams Syndrome
Stress
Treatment
N/AClinical Study ID
NCT01397110
2011-07-12
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- signed consent form
- men and women> 18 years <80 years
- APAH with congenital heart defects with / without Eisenmenger syndrome (WHO functionalclass II-IV), invasively diagnosed by right heart and left heart catheterization: meanpulmonary arterial pressure (mPAP) ≥ 25 mmHg, with targeted PAH medication for atleast two months stable before study inclusion (exception: compensated WHO class IIwithout vasodilating drug therapy)
Exclusion
Exclusion Criteria:
- Pregnancy or lactation
- Change in medication during the last 2 months
- severe walking disturbance
- uncertain diagnoses
- No previous invasively confirmation of PH
- acute diseases, infections, fever
- Serious lung disease with FEV1 <50% or TLC <70% of target
- Further exclusion criteria are the following diseases: active myocarditis, unstableangina pectoris, exercise-induced ventricular arrhythmias, recurrent syncope within 4weeks before study entry
Study Design
Total Participants: 50
Study Start date:
January 01, 2012
Estimated Completion Date:
December 31, 2025
Connect with a study center
: Center for pulmonary Hypertension, Thoraxclinic Heidelberg
Heidelberg, 69126
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.